These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12448579)

  • 21. Design and analysis of bridging studies with prior probabilities on the null and alternative hypotheses.
    Zeng D; Pan Z; Lin DY
    Biometrics; 2020 Mar; 76(1):224-234. PubMed ID: 31724739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The U.S. draft guidance regarding population and individual bioequivalence approaches: comments by a research-based pharmaceutical company.
    Hauschke D; Steinijans VW
    Stat Med; 2000 Oct; 19(20):2769-74. PubMed ID: 11033574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Some statistical considerations on the FDA draft guidance for individual bioequivalence.
    Hsuan FC
    Stat Med; 2000 Oct; 19(20):2879-84. PubMed ID: 11033582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating Similarity of Dose-Response Relationships in Phase I Clinical Trials-Case Study in Bridging Data Package.
    Ollier A; Zohar S; Morita S; Ursino M
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33572323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Summary report of second EUFEPS/AAPS conference on global harmonization in bioequivalence.
    Chen ML; Blume H; Beuerle G; Mehta M; Potthast H; Brandt A; Schug BS; Ducharme M; Endrenyi L; Gallicano K; Schuirmann D; Welink J
    Eur J Pharm Sci; 2019 Jan; 127():24-28. PubMed ID: 30342171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian approach to average bioequivalence using Bayes' factor.
    Ghosh P; Khattree R
    J Biopharm Stat; 2003 Nov; 13(4):719-34. PubMed ID: 14584718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A predictive Bayesian approach to the design and analysis of bridging studies.
    Gould AL; Jin T; Zhang LX; Wang WW
    J Biopharm Stat; 2012 Sep; 22(5):916-34. PubMed ID: 22946940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian approach to evaluation of bridging studies.
    Liu JP; Hsiao CF; Hsueh H
    J Biopharm Stat; 2002 Aug; 12(3):401-8. PubMed ID: 12448580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individual bioequivalence testing under 2x3 designs.
    Chow SC; Shao J; Wang H
    Stat Med; 2002 Mar; 21(5):629-48. PubMed ID: 11870806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weighted evidence approach of bridging study.
    Tsou HH; Tsong Y; Liu JT; Dong X; Wu Y
    J Biopharm Stat; 2012 Sep; 22(5):952-65. PubMed ID: 22946942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Bayesian methods for multivariate bioequivalence measures.
    Molina de Souza R; Achcar JA; Martinez EZ
    J Biopharm Stat; 2009; 19(1):42-66. PubMed ID: 19127466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A group sequential approach to evaluation of bridging studies.
    Hsiao CF; Xu JZ; Liu JP
    J Biopharm Stat; 2003 Nov; 13(4):793-801. PubMed ID: 14584723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration.
    Hauck WW; Hyslop T; Chen ML; Patnaik R; Williams RL
    Pharm Res; 2000 Apr; 17(4):375-80. PubMed ID: 10870978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sample size determination for a specific region in a multiregional trial.
    Ko FS; Tsou HH; Liu JP; Hsiao CF
    J Biopharm Stat; 2010 Jul; 20(4):870-85. PubMed ID: 20496211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of moment-based and probability-based criteria for assessment of follow-on biologics.
    Chow SC; Hsieh TC; Chi E; Yang J
    J Biopharm Stat; 2010 Jan; 20(1):31-45. PubMed ID: 20077247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization.
    O'Neill RT
    Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report.
    Chen ML; Shah VP; Crommelin DJ; Shargel L; Bashaw D; Bhatti M; Blume H; Dressman J; Ducharme M; Fackler P; Hyslop T; Lutter L; Morais J; Ormsby E; Thomas S; Tsang YC; Velagapudi R; Yu LX
    Eur J Pharm Sci; 2011 Nov; 44(4):506-13. PubMed ID: 21946259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trials for drug registrations in Asian-Pacific countries: proposal for a new paradigm from a statistical perspective.
    Shih WJ
    Control Clin Trials; 2001 Aug; 22(4):357-66. PubMed ID: 11514037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample sizes for bioequivalence studies.
    Metzler CM
    Stat Med; 1991 Jun; 10(6):961-9; discussion 969-70. PubMed ID: 1876786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profile analysis for assessing in vitro bioequivalence.
    Cheng B; Shao J
    J Biopharm Stat; 2002 Aug; 12(3):323-32. PubMed ID: 12448574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.